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Abstract: Dengue is one of the most important arboviral infection worldwide, infecting up to 390 million people and 
causing 25,000 deaths annually. Although a licensed dengue vaccine is available, it is not efficacious against dengue 
serotypes that infect people living in South East Asia, where dengue is an endemic disease. Hence, there is an urgent need 
to develop an efficient dengue vaccine for this region. Data from different clinical trials indicate that a successful dengue 
vaccine must elicit both neutralizing antibodies and cell mediated immunity. This can be achieved by designing a multi-
epitope peptide vaccine comprising B, CD8+ and CD4+ T cell epitopes. As recognition of T cell epitopes are restricted by 
human leukocyte antigens (HLA), T cell epitopes which are able to recognize several major HLAs will be preferentially 
included in the vaccine design. While peptide vaccines are safe, biocompatible and cost-effective, it is poorly 
immunogenic. Strategies to improve its immunogenicity by the use of long peptides, adjuvants and nanoparticle delivery 
mechanisms are discussed.  
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INTRODUCTION 
 Dengue is a mosquito-borne viral disease that 
occurs mainly in the tropical and subtropical regions [1]. It 
causes an annual estimated 390 million infections, of which 
500,000 require hospitalization and 25,000 deaths are 
reported [2, 3]. Dengue is transmitted to humans by female 
Aedes aegypti or Aedes albopictus mosquitoes infected with 
the dengue virus. Most patients have asymptomatic or self-
limiting dengue fever (DF), however others may suffer from 
life-threatening dengue haemorrhagic fever (DHF) or dengue 
shock syndrome (DSS) [4]. Severe dengue is a potentially 
deadly complication due to plasma leakage, fluid 
accumulation, respiratory distress, severe bleeding, and 
organ impairment.  
Dengue virus belongs to the Flaviviridae family and 
is endemic in more than 100 countries worldwide [3]. 
Dengue infection can be caused by four distinct, but closely 
related serotypes, DENV-1, DENV-2, DENV-3 and DENV-
4, sharing 65-70% sequence homology [5]. Dengue virus has 
a positive stranded ~11kb RNA genome, encoding for a 
polypeptide chain of approximately 3400 amino acids. This 
polypeptide is made up of three structural proteins (capsid, 
membrane and envelope), and seven non-structural (NS) 
proteins (NS1, 2a, 2b, 3, 4a, 4b and 5). The structural 
proteins form the external viral structure, while the NS 
proteins are involved in the viral replication machinery.  
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Host immunity against dengue virus 
Immunity against viral infection can be divided into the 
innate and adaptive arms. Upon entry of viruses into the 
human host, it is first recognized by the innate immunity, 
which is the first line of defense against pathogens. Cells of 
the innate immunity recognize viral components as being 
‘foreign’ by using different types of pattern recognition 
receptors such as Toll-like receptors (TLRs), nucleotide 
oligomerization domain-like receptors (NOD) and retinoic 
acid-inducible gene I-like receptors (RLRs). These receptors 
trigger downstream intracellular signaling cascades, eliciting 
the production of pro-inflammatory cytokines and 
chemokines [6, 7].  Of these, type I interferons (IFNs) are the 
primary cytokines that inhibit viral replication in both 
infected and uninfected cells [8]. In addition, type I IFNs 
promote the initiation of adaptive immune responses by 
mediating activation of dendritic cells (DCs), enhancing the 
effector functions of macrophages and lymphocyte, and 
stimulating the humoral response to neutralize viruses [9].  
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Adaptive immunity against viral infections are mediated 
by antibodies (humoral immunity) and cellular mediated 
immunity. Humoral immunity is mediated by B cells, which 
when stimulated by CD4+ T helper cells, secrete specific 
anti-viral antibodies. These antibodies “neutralize” the virus 
by binding to its envelope or capsid proteins, thereby 
preventing its attachment and entry into host cells. 
Antibodies can also function to opsonize viral particles and 
promote their destruction by phagocytes such as 
macrophages and neutrophils [9]. Viral neutralization and 
opsonization by antibodies are only effective when they are 
extracellular.  
Once virus has infected the cells, its elimination is 
mediated by the killing of the infected cell by CD8+ 
cytotoxic T-lymphocytes (Tc). Viral proteins are degraded by 
the proteolytic enzymes in the endosome, and resulting 
peptides are loaded on either major histocompatibility 
complex (MHC) class I or class II molecules. Recognition of 
viral peptides bound to MHC-I by T-cell receptor (TCR), 
followed by co-stimulatory signals generated by CD4+ T-
helper  (Th) cells and DCs [10] are necessary to stimulate the 
activation of CD8+ T-cells. Activated CD8+ Tc release 
cytotoxic granules containing granzymes, perforins and 
granulysin that induce the apoptosis of viral-infected cells, 
and cytokine production of TNF-α and IFN-γ. 
During the primary DENV infection, antibodies against 
the virus are able to neutralize the viral infection and confer 
lifelong protection against it. Upon heterologous infection 
with another DENV serotype, there is an initial phase of 
cross-protection. However, these antibodies are short-lived, 
and are superseded by the non-neutralizing cross-reactive 
antibodies [11]. They form antibody-virus complexes and 
bind to the FcγR receptors of circulating monocytes and 
macrophages, allowing the heterologous DENV to infect 
these cells more efficiently, leading to high viral replication 
and viral load, eventually causing a more severe form of 
dengue infection. This phenomenon is known as antibody-
dependent enhancement (ADE) [12, 13].  
While the humoral response to secondary heterologous 
dengue infection leads to ADE, the equivalent aberrant 
response in the cellular immunity is termed the “original 
antigenic sin” [14]. The original antigenic sin, or the Hoskins 
effect refers to the propensity of the immune system to favor 
the immunological memory of the first infecting antigen, 
when an altered version of the antigen is encountered later. 
In the case of dengue, during the secondary dengue infection 
(with a virus serotype different from the primary infection), 
the cellular immunity is dominated by cross-reactive 
memory T cells generated during the first infection. 
Although the cross-reactive T cells are activated more 
rapidly and are present in large numbers, they are inefficient 
in lysis of DENV-infected cells due to sub-optimal TCR 
triggering. This results in poor virus clearance from the host 
[14, 15].  
The exact role of T cells, as being protective or 
pathologic during dengue infection is still being debated [16-
18].  Initial research in this area mainly support the 
pathological role of T cells in dengue. The delay in viral 
elimination leading to a more severe dengue 
immunopathology observed during secondary infections 
could be due to lower affinity CD8+ T cells that were 
dysfunctional [14]. Several studies highlighted the 
observation of DENV-specific T cells that produced high 
levels of TNF-α (versus IFN-γ) during secondary infection as 
a potential cause of immunopathology [19-21]. High 
amounts of TNF-α can lead to vascular leakage, a symptom 
of severe dengue. Accordingly, as IFN-γ is implicated in 
antiviral activity, the lower IFN-γ secretions observed during 
heterologous infection indicates reduced clearance of viral 
infected cells. Apart from the TNF-α / IFN-γ balance, the 
lack of cytotoxic activity of T cells is also a contributing 
factor to the negative role of T cells in secondary infections 
[22]. 
Of late however, data from studies on CD8+ T cells 
support its protective role in secondary dengue infections. A 
recent study by Rivino et. al. (2015) reported that the 
DENV-specific CD8+ T cells in patients with acute 
secondary dengue infection had anti-viral effector 
phenotype, characterized by high IFN-γ, CD107a+ and low 
TNF-α cytokines [23]. It was previously suggested that high 
levels of TNF-α found in serum of severe dengue patients 
could be the causal factor of plasma leakage [24]. The TNF-
α cytokine may not originate from dengue-specific T cells, as 
it has been reported that these cells were only detected in the 
blood of dengue infected patients post-viremia resolution, 
indicating that it was unlikely that T cells were linked to 
plasma leakage [25]. Furthermore, individual HLA alleles 
have been implicated in dengue susceptibility or protection 
(Table 2). In a study performed on dengue seropositive 
individuals from Sri Lanka, the protective CD8+ T cells had 
higher response magnitude and were polyfunctional in terms 
of cytokine production [26].  
Current prevention options for dengue 
 The burden and costs of dengue continues to grow, 
with an estimation of more than 96 million symptomatic 
dengue infections in the world annually. At present, the most 
successful method of controlling dengue is based primarily 
on mosquito vector control and dengue case management, 
but these strategies are only partially successful.  Of late, 
there has been an increasing amount of research in the field 
of dengue vaccine development. Although one vaccine 
(Dengvaxia®) has been registered and several others are in 
late phases of clinical trials, so far, none has provided 
effective protection against all DENV serotypes. The 
challenge in dengue vaccine development arises from the 
presence of four serotypes of viruses that can cause the 
disease, and the previous observations that subsequent 
heterologous infection often result in a more severe form of 
dengue, implying that natural humoral or cell-mediated 
immune response against the primary dengue infection is 
insufficient to confer complete protection against the 
heterologous DENV.  
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Dengvaxia® CYD-TDV by Sanofi Pasteur is 
currently the only vaccine approved for use in endemic 
populations. It is a tetravalent live-attenuated vaccine (LAV), 
composed of prM/E genes of the four DENV serotypes on 
the 17D yellow fever RNA backbone [27]. The yellow fever 
virus belongs to the same virus family as dengue, and has 
previously shown good immunogenicity and safety profile as 
a vaccine [28]. In general, Dengvaxia® showed higher 
efficacy in DENV seropositive recipients (having pre-
existing anti-DENV antibodies) compared to seronegative 
recipients [29, 30]. The efficacy of Dengvaxia® varied 
according to serotype and age of the vaccinees. In 
individuals above 9 years old, higher overall protection was 
observed against DENV-4 (83.2%) and DENV-3 (73.6%), 
and was less efficient against DENV-1 (58.4%) and DENV-
2 (47.1%) [31]. Protection against DENV-2 was particularly 
low in the Asian population at only 36.8% [31], although 
seroconversion was observed [32]. Efficacy of Dengvaxia® 
was higher against severe dengue and hospitalization in 
recipients above 9 years old (90.9% and 81.6%, 
respectively), compared to those below 9 years of age 
(44.5% and 56.1%, respectively) [31].  
Reduced efficacies to all serotypes were observed in 
children less than 9 years old, in decreasing order from 
DENV-3 (62.1%), DENV-4 (51.7%), DENV-1 (46.6%) and 
DENV-2 (33.6%). In a large phase III study that involved 
10,275 children from five Asian countries, Dengvaxia® 
CYD14 only produced an endpoint of 56.5% efficacy [29]. 
Asian children (2-5 years old) receiving Dengvaxia® had 
significantly higher hospitalization risk for virologically 
confirmed dengue cases, 15 cases in the vaccine group 
versus one case in the control group [30, 31, 33]. In addition, 
the number of serious adverse effects reported in the 
vaccinees (402 cases) was almost double of that in the 
control group (245 cases) [29], raising serious concerns 
against the use of Dengvaxia® as the preferred vaccine 
against dengue infection.   
Although Dengvaxia® has several shortcomings, it 
is currently the only licensed vaccine against dengue 
infection. WHO has recommended the use of Dengvaxia® in 
countries where dengue is endemic, and for patients of 9 – 
45 years old [34]. The lower efficacy of Dengvaxia® against 
DENV-1 and DENV-2, coupled with its low safety levels in 
children below 9 years old calls for the need of a more 
efficacious vaccine candidate, primarily in regions where 
DENV-1 and -2 are the prevailing serotypes, such as in 
Malaysia and Singapore [35-37]. The main mode of immune 
response of Dengvaxia® seems to be via the humoral route, 
by eliciting neutralizing antibodies. Despite the 
seroconversion against different serotypes, the lack of 
protection of Dengvaxia® (in particular against DENV-2) 
indicates that neutralizing antibodies alone are insufficient to 
confer protection, and there is a need for vaccine developers 
to pay attention on eliciting cellular immunity against 
dengue [26, 38]. 
Few other vaccine candidates are currently 
undergoing clinical trials, of which TV003/ TV005 and 
DENVax (TDV) are in the frontline [39]. TV003 and TV005 
are tetravalent LAVs developed by the National Institute of 
Allergy and Infectious Diseases (NIAID) in United States. 
The composition of TV003 and TV005 differs by its dose of 
the attenuated DENV-2, which was 10 fold higher in TV005 
[40]. TV003/TV005 were attenuated by creating deletion of 
30/31 base pairs in the 3’ untranslated for each serotype, and 
for DENV-2, the prM/E proteins were substituted on the 
rDENV-4∆30 backbone [41]. TV003 is currently in phase III 
clinical trial (ClinicalTrials.gov Identifier: NCT02406729) 
while TV005 is in phase II trial (NCT02678455). The overall 
tetravalent neutralizing antibody response reported for 
TV003 and TV005 were 74.0% and 90.0%, respectively [39, 
42]. Seroconversion rates for TV005 was more balanced 
between different serotypes, with 92% against DENV-1 and 
97% against DENV 2-4, when compared to TV003 [42]. So 
far, results from clinical trials have been showing promising 
outcomes. In the phase II study, all 21 individuals vaccinated 
against TV003 and challenged with rDEN2∆30 did not 
develop viremia, neutropenia or rash and was protected from 
infection. All patients were also protected against the second 
challenge administered 6 months after the initial vaccination 
[43]. In contrast to Dengvaxia®, TV003 conferred higher 
degree of protection against DENV-2, and induced strong 
CD8+ T cell responses, directed against the highly conserved 
non-structural protein epitopes of all DENV serotypes [44].  
DENVax (TDV) is a tetravalent LAV developed by 
Takeda Pharmaceuticals, containing the prM and E genes of 
DEN-1, -3, and -4 on the DENV-2 PDK-53 genetic 
backbone [33]. The DENV2-PDK-53 has been attenuated by 
53 serial passages in primary dog kidney cells, and further 
attenuated by gene mutation of NS3 [33, 39]. Phase I studies 
for DENVax were performed in participants aged 18-45 
years old in United States and Columbia. Different doses and 
routes of vaccine administration were evaluated. 
Neutralizing antibodies were produced against all serotypes 
regardless of dose and injection routes. Approximately 62% 
of the participants were able to seroconvert to all four 
serotypes 30 days after the second vaccination dose was 
administered [45]. Titers of neutralizing antibodies varied 
according to the serotype, with the highest against DENV-1 
and -2, and lowest to DENV-4 [46]. In the multicentre, 
double-blind  phase II studies conducted in Puerto Rico, 
Columbia, Singapore and Thailand,  DENVax was well 
tolerated with no serious adverse events reported, 
irrespective of pre-vaccination dengue exposure profile and 
age of volunteers [46]. In addition to eliciting neutralizing 
antibodies, as the architecture of DENVax contained the 
genes that encode non-structural proteins of DENV-2, it was 
able to elicit multifunctional CD8+ T cell responses against 
NS1, NS3 and NS5 proteins of DENV-2, which was able to 
cross-react to the same proteins in other serotypes [33, 47, 
48]. 
Other anti-dengue vaccine candidates that are 
currently in the pipeline include live attenuated vaccines, 
inactivated vaccines, recombinant vector vaccines, DNA 
vaccines and subunit vaccines [33, 49-53]. The peptide based 
vaccine strategy for dengue is currently intensely researched, 
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via discovery of specific B, Tc and Th epitopes (Table 1) and 







Table 1. Distribution of CD4+ and CD8+ epitopes based on dengue proteins 
 
No. Protein No. of epitopes Subset Ref. 
1 C, NS2A, NS3, NS4B, NS5 8 CD8 [54] 
2 C, NS4B, NS5 4 CD8 [55] 
3 C 2 CD4 [56] 
4 NS3 2 CD8 [57] 
5 NS3 1 CD8 [14] 
6 NS3 3 CD4 [58] 
7 NS3 2 CD4 [21] 
8 NS3 1 CD8 [59] 
9 NS3 1 CD4 [60] 
10 NS3 1 CD8 [61] 
11 NS3 1 CD4 [62] 
12 NS3 2 CD4 [63] 
13 NS3 1 CD8 [64] 
14 NS3, NS4B, NS5 10 CD8 [65] 
15 NS3 1 CD8 [22] 
16 NS3 1 CD8 [66] 
17 NS3 1 CD8 [20] 
18 NS3, NS5 2 CD8 [67] 
19 NS3 3 CD8 [68]  
20 NS3, NS4B, NS5 5 CD8 [69] 
21 NS5 14 CD8 [70] 
22 E 8 CD8 [71] 
23 E 3 CD8 [72] 
24 C, PrM, M, E, NS1, NS2A, NS3, NS4A, NS4B, NS5 18 CD4, CD8 [73] 
25 C, E, NS2B, NS3, NS4A, NS4B, NS5 13 CD8 [74] 
26 C, M, E, NS2A, NS3, NS4B, NS5 25 CD8 [26] 
27 E, NS2A, NS3, NS4B 9 CD8 [75] 
28 M, E, NS1, NS2A, NS2B, NS3, NS4A, NS4B 16 CD4, CD8 [76] 
29 C, NS1, NS3 5 CD4, CD8 [77] 
30 E, NS2A, NS4A, NS4B 7 CD8 [78] 
31 NS2b, NS3, NS4a, NS4b, NS5 8 CD8 [79] 
32 C, E, NS3 4 CD4 [80] 
33 C, M, E, NS2A, NS4B, NS5 12 CD8 [81] 
34 C, E, NS3, NS4B, NS5 5 CD8 [82] 
35 E, NS4A, NS4B 4 CD8 [15] 
36 C, PrM, M, E, NS3, NS4A 47 CD4, CD8 [83] 
37 C, M, E, NS1, NS2A, NS2B, NS3, NS4B NS5 30 CD4, CD8 [84] 
38 E, NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5 19 CD4, CD8 [85] 
39 E, NS1 2 CD8 [86] 
40 NS1, NS3, NS5 16 CD4 [87] 
41 NS3, NS5  5 CD8 [88]  
42 E  10 CD4 [89] 
43 E  3 N/A [90] 
44 prM  4 N/A [91] 
45 E  9 CD4 [92] 
46 E, NS1, NS3, NS5  29 N/A [93] 
47 E, NS2B, NS3, NS4A, NS4B, NS5  12 CD4, CD8 [94] 
48 E  7 CD4 [95] 
N/A – not available 
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Peptide vaccines compared to other types of dengue 
vaccinations 
Peptide based vaccines are currently being 
developed to be used both as therapeutic or prophylactic 
treatment for a multitude of diseases, ranging from cancers 
and viral infections, to allergies and Alzheimer’s disease. A 
total of 475 clinical trials (266 in phase I, 198 in phase II, 11 
in phase III) that used peptide vaccines for different diseases 
have been reported in ClinicalTrials.gov, a database of the 
US National Institute of Health (Figure 1). So far, no peptide 
vaccine has reached phase IV trial. While the number of 
clinical trials reported from March 2014 (506 trials) [96] to 
date (15 June 2017, 475 trials) has not changed much, it still 
signifies a wide-spread interest of this vaccination strategy. 
Most of the peptide vaccines in clinical trials were against 
different cancers, followed by viral infections, allergy and 
auto-immune diseases (Figure 2). The viral based peptide 
vaccines were in phase I (29 clinical trials) and phase II (13 
clinical trials) against HIV, HBV, HCV and CMV (Figure 
2). No peptide vaccine against dengue is currently in clinical 
trial.  
Currently, there are 103 clinical trial entries in 
ClinicalTrials.gov using the search terms “dengue” and 
“vaccine” (data accessed on 15 June 2017). This is a 72% 
increase of the number of trials, compared to the 60 studies 
reported in 2014 [41].  
In dengue research, all four vaccines which are 
currently in the late clinical trial development stages (phase 
II and above) have been designed using the live attenuated 
virus (LAV) strategy. Although LAVs are very potent 
immunological stimulators, and are able to ideally generate 
appropriate immune responses to protect the host against 
subsequent viral infections, there are several risks associated 
with LAVs. As LAVs are living organisms, there is a risk of 
reversion to its original pathogenic form, which is capable of 
causing disease. This has been previously observed in the 
cases of vaccine-associated paralytic poliomyelitis and 
disease-causing vaccine-derived poliovirus associated with 
oral polio vaccine [97, 98]. LAVs could cause potential harm 
to immunocompromised patients (eg. HIV infected) as they 
may not be able to respond adequately to the vaccine [99].  
Other disadvantages include high storage and transportation 
costs, as LAVs usually require storage at low temperatures to 
remain active. In the case of dengue, as it can be caused by 4 
serotypes, LAVs need to be prepared from all serotypes, and 
the resulting downstream growth and purification of these 
strains can be laborious and costly.  
In an adaptive immunological response against 
foreign antigens, only short segments of the antigens (termed 
epitopes) are recognized by the B- and T-cell receptors 
[100]. Synthetic peptide vaccines (or “designer” vaccines) 
are composed of selected epitope(s) of the antigenic protein, 
thus enabling the induction of highly targeted immune 
responses. Using well defined antigen(s), the disadvantages 
commonly associated with whole pathogen vaccine, such as 
reversion to the wild type virus and contamination with other 
antigenic components can easily be avoided [101]. 
Compared to conventional vaccines, peptide synthesis is 
highly reproducible, fast and cost effective [96, 101]. 
However, despite its high safety profile compared to live 
attenuated vaccines, synthetic peptide vaccines are generally 
poorly immunogenic. They are susceptible to enzymatic 
degradation, making them unstable in vivo [101]. These 
shortcomings can be overcome by using several strategies, 
which will be explored in a greater detail in this review, such 
as increasing peptide length, addition of T-helper epitope 
sequences, addition of the third signal, adjuvants, delivery 
methods, or a combination of several approaches. The final 
goal is to develop a safe, reproducible and genetically stable 
vaccine, which is capable of inducing the appropriate 
immune response. 
 
Viral T-cell epitopes are HLA restricted 
 Once the viral antigen is taken up by the antigen 
presenting cells (APCs) such as DCs, it is processed by 
proteolytic degradation in the proteasomes, and the resulting 
peptides are transported into the endoplasmic reticulum.  
Here, CD8+ T cell epitopes of the virus binds to MHC class I 
molecule, and the complex is expressed on the cell surface of 
the APC [102]. MHC (or human leukocyte antigens, HLA in 
humans), are one of the most highly polymorphic genes 
determining specificity to antigen epitopes [103, 104]. 
MHC-I molecules are encoded by HLA-A, -B and –C 
(presenting CD8+ T cell epitopes), while MHC-II molecules 
are encoded by HLA-DP, -DQ and –DR genes (presenting 
CD4+ T cell epitopes). The polymorphic residues within the 
HLA molecule determine the peptide binding specificity, and 
this is termed HLA restriction. One of the main challenges in 
designing peptide vaccines is selecting the correct epitope, as 
T cell epitopes are restricted by HLA molecules. 
Furthermore, as there is a vast diversity of HLA types in a 
population,  individual patients could recognize a different 
set of epitopes for the same antigen [101, 105]. However, 
several studies have demonstrated that some HLA 
supertypes can share high degree of peptide binding 
specificities. In approximately 90% of people, three peptide 
binding specificities are shared among HLA-A02, A03 and 
B07 [106, 107]. 
The HLA gene is located on chromosome 6p21 
which is in close proximity to many other immune-related 
genes. Many studies have found that some HLA alleles were 
associated to disease susceptibility, while others were 
protective. Similarly, in dengue, studies investigating the 
association of HLA alleles to dengue susceptibility or 
protection have been carried out in many countries (Table 2). 
Most HLA associations have been investigated for class I 
HLA molecules, and very little is known regarding the role 
of HLA-II molecules. There seems to be a great diversity in 
HLA-alleles that confer susceptibility / protection across 
various populations (Table 2). This is perhaps due to two 
reasons. First, it has been shown that HLA alleles are 
specific to ethnicity and geographical location [108, 109]. 
Second, the four co-circulating dengue virus serotypes could 
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further influence the HLA-specificity leading to the 
heterogeneous HLA-molecules associated with protection / 
susceptibility of dengue.  
 
Table 2. Susceptible and protective HLA to dengue based on population 
 
Population Susceptible HLA Protective HLA Reference 
Malaysia (total) HLA-B*53 HLA-A*03 [110] 
  HLA-B*18  
    
Malaysia (Malay population) HLA-B*13  [110] 
    
Philippines  (children)  HLA-A*3301(severe dengue) [111] 
    
Brazil (Latin American 
population) 
HLA-B*44  HLA-B*07, HLA-DR*13 [112] 
    
Brazil (White population) HLA-DQ*01  [113] 
    
Brazil HLA-A*01 (DHF)  [114] 
    
Cuba HLA-A*01 HLA-B*14 [115] 
  HLA-A*29  
    
 HLA-A*31 (DHF) HLA-DRB1*07 [73] 
 HLA-B*51 HLA-DRB1*04  
    
Vietnam (children) HLA-A*24 (DHF) HLA-A*33 (DHF) [88] 
    
 HLA-A*2402 (DHF/DSS) HLA-DRB1*0901 (DSS) [116] 
 HLA-A*2403 (DHF/DSS)   
 HLA-A*2410 (DHF/DSS)   
    
Mexico HLA-DQB1*0302 (DHF, not DF) HLA-B*35 (DF) [117] 
 HLA-DQB1*0202 (DF only)   
    
Sri Lanka HLA-DRB1*08 (DHF/DSS)  [118] 




    
Thai HLA-B*51 (DHF, secondary infection) HLA-A*0203 [119] 
 HLA-A*0207 (DHF) HLA-B*44  
 HLA-B*52 (DHF, primary infection) HLA-B*62  
  HLA-B*76  
  HLA-B*77  
    
 HLA-A*02 (secondary infection) HLA-B44 (DHF, secondary infection) [120] 
 HLA-A*01 (secondary infection)   
 HLA-A*03 (secondary infection)   
    
 HLA-A*02 HLA-B*13 [121] 
    
Venezuela HLA-B*57 (DF) HLA-A*03 (DHF) [122] 
 HLA-B*40 (DHF)   
    
Jamaica HLA-A*24 HLA-A*23 [123] 
 HLA-DRB5*01 HLA-CW*04  
 HLA-DRB5*02 HLA-DQB1*02  
  HLA-DQB1*03  
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T cell epitope mapping by experimental or predictive 
approaches 
Epitopes can be broadly classified into linear or 
conformational epitopes, based on their interaction with the 
paratope. T cell epitopes (specific to either CD4+ or CD8+ 
cells) are linear, where its sequence is continuous, based on 
the primary amino acid sequence of the antigen. B cell 
epitopes can be linear or conformational. Conformational 
epitopes are based on the three-dimensional protein structure 
interaction with the B-cell receptor, therefore its amino acid 
sequence is discontinuous.  
Current vaccination formulations against dengue 
target the humoral immunity, and have been shown to be 
insufficient to effectively protect against the infection. 
Cytotoxic T cells play an important role in killing infected 
cells and control viremia of dengue virus. Hence, we focus 
the scope of this review on the use of T cell epitopes in 
peptide vaccine formulations, and the different strategies that 
could be employed to improve immunogenicity of the 
vaccine formulation. 
The identification of T cell epitopes of antigens is 
the first step in designing peptide-based vaccines. This can 
be achieved either experimentally, using functional assays, 
or by in silico predictive approaches, with each method 
having its own advantages and limitations. An experimental 
method that is commonly used to identify T cell epitopes in 
dengue is by synthesizing a peptide library consisting of 
short overlapping synthetic peptides, spanning either the 
whole virus protein, or focusing on a specific protein of 
interest. These peptides are then tested using a functional 
assay such as ELISPOT to measure the release IFN-γ from 
PBMCs isolated from patients [83, 84, 124], intracellular 
cytokine staining of IFN-γ and TNF-α from patients CD4+ 
and CD8+ T cells of patients [19], or in vitro lymphocyte 
proliferation response of peptide-primed lymphocytes [89]. 
Alternatively, similar functional assays may also be 
performed using purified recombinant protein fragments 
[89]. MHC-microarray is another technique performed by 
spotting MHC-I molecules on microarray slides, and 
interacting it with peptides that can be recognized by T-cells. 
By adding anti-cytokine antibodies to this assay, the amount 
of cytokine secreted by the target T cell can be measured, 
similar to that in an ELISPOT. This method has been used to 
map T cell epitopes in HIV [125], but has not gained 
popularity due to high cost and complexity of sample 
preparation and instrumentation. In cell ELISAs, the solid 
multi-well surface is first coated with an anti-cytokine 
antibody, followed by the addition of peptides and T cells. If 
the T cells recognize the peptide, it would secrete cytokines 
which can be detected by capture of the solid-phase 
antibody. T cell epitope mapping of a multiple sclerosis 
related intracellular pathogen, Mycobacterium avium, has 
been delineated using this method [126].  
The binding of peptide epitope to HLA molecules is 
the pre-requisite of peptide-TCR recognition and eventually 
T cell activation and differentiation. Identification of the 
antigenic peptides that bind to HLA molecules in vivo can 
now be performed using immunoproteomics approaches. 
Compared to other experimental approaches, this method 
identifies clinically-relevant epitopes in a straightforward 
and direct manner, not subjected to any biases such as 
selection of dominant epitopes based on its level of IFN-γ 
secretion, or predictive scores of HLA-binding based on 
certain algorithms. This approach has been used to identify 
the MHC-I binding epitopes of dengue virus [54, 55]. The 
MHC-I epitopes identified originated from both structural 
and non-structural DENV proteins, indicating that Tc 
epitopes of DENV is more wide-spread than previously 
thought [26]. More importantly, this approach enabled the 
identification of two promiscuous Tc epitopes, binding to 
HLA-A2 and HLA-A24 [54], which allows for broader 
vaccine coverage and efficacy. 
            While experimental methods are unbiased, epitope 
identification involves testing many peptides, rendering this 
approach costly and tedious. Predictive bioinformatics 
approaches, on the other hand, are high throughput and 
economical as only the predicted epitopes with high 
confidence would be tested in functional biological assays to 
validate its activity. The bioinformatics approach has been 
used heavily in predicting T cell epitopes in dengue. The 
first step of in silico T cell epitope prediction is to predict 
peptide binding to HLA alleles and supertypes. Several 
prediction methods are available, based on the method of 
machine learning used. These include position specific 
scoring matrices (PSSM) such as RANKpep [80, 82], 
SYFPEITHI [73, 78, 82], BIMAS [73], support vector 
machines (SVM) [127, 128] and artificial neural network 
(ANN) (netMHC [129]. The previously listed algorithms 
identify peptide binding to individual HLA alleles. Now, it is 
possible to predict promiscuous peptide binding to HLA, 
based on its binding grove, termed panHLA binding. Several 
pan-specific algorithms exists such as MULTIPRED [130] 
netMHCpan [70, 131], KISS [132], TEPITOPEpan [133], 
Pick-Pocket [134] and ADT [135]. Once the HLA-binding 
peptide is predicted, other computational algorithms that 
model the MHC class I antigen processing, such as 
proteosomal cleavage, transport associated protein (TAP) 
transport (eg. NetCTL [79, 136] and MHC-PATHWAY 
[137]) and hydopathy [138] may be applied to improve the 
prediction stringency. Finally, selected predicted epitopes 
should be tested using functional biological assays to 
validate its biological function. The predictive approaches 
have its own limitations - identification of false positive 
epitopes, and the poor discrimination between MHC-binding 
peptides which are T cell epitopes or non-epitopes. 
 
Peptide length affects antigenicity 
 Immunogenicity has been shown to be dependent 
on peptide length [139, 140]. Short peptides (8 -11 amino 
acids) are able to bind directly to the MHC-I molecule, 
without the need of processing by professional APCs [141, 
142]. As a consequence, such short peptides containing the 
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minimal Tc epitopes are capable of binding to MHC-I 
molecules on any cell, including non-professional APCs, 
which lack the co-stimulatory molecules required to generate 
effector Tc cells, resulting in CD8+ T cell tolerance [143, 
144]. On the other hand, longer peptides (more than 17 
amino acids) have been reported to require proteosomal 
processing by APCs prior to its presentation by MHC 
molecules [145]. Synthetic peptides that were extended so 
that they were now sufficiently long to be processed by DCs 
were able to trigger the expansion of effector Tc [146]. 
Several studies that performed direct comparisons between 
minimal Tc  epitopes and long peptides containing the Tc 
epitopes in different antigens (human papillomavirus, 
ovalbumin or adenovirus) have shown that longer peptides 
were able to elicit more robust and effective Tc responses 
[140, 147]. 
 
Improving the efficacy of synthetic peptides – adding the 
CD4+ T cell epitope 
Activation of cytotoxic T cells requires two signals. The 
first signal is the recognition of the antigen via its 
presentation on the MHC–I molecules by the T cell receptor 
on the naïve cytotoxic T cells. The second signal involves 
the interaction between co-stimulatory molecules which are 
expressed on the surfaces of APC and the naïve cytotoxic T 
cell. T-helper cells are among the APCs that express co-
stimulatory molecules. Experiments performed by co-
injecting the minimal epitopes of Tc and Th were successful 
in preventing Tc tolerance [140], and augmenting the Tc 
response [148-150] as both signal 1 and 2 were present, 
allowing Tc cells to mature into effector cells. The delivery 
of multi-epitope peptide vaccines by linking both the 
minimal epitopes of Tc and Th synthetically as a single 
peptide appears to be more efficient than co-injecting a 
mixture of each epitope [151-153]. As the multi-epitope 
vaccine is now a longer peptide, it is highly likely that its 
increased potency could be attributed to it being processed 
by the APCs, ensuring the accurate Tc epitopes presented on 
MHC-I, as well as the activation via co-stimulatory 
molecules. In fact, a 15-mer peptide which was initially 
reported to be able to induce Tc responses in the absence of 
any adjuvants, was later identified to also contain a Th 
epitope, which likely aided this response [154].  
As in MHC-I, MHC-II genes are also highly 
polymorphic, and the recognition of Th epitopes are 
restricted by its HLA alleles. To overcome this, an artificial 
pan HLA-DR helper T-lymphocyte epitope (PADRE) 
peptide was constructed by introducing anchor residues for 
different DR motifs within a polyalanine backbone to 
generate a ‘universal’ T-helper epitope [10]. PADRE binds 
to majority of the human HLA-DR receptors with moderate 
to high affinity, hence it is able to overcome the HLA class 
II restriction by providing ‘universal’ immune stimulation in 
a MHC-heterologous population [101, 155]. PADRE has 
been shown to increase the immune response to associated 
peptide antigens. In a study using HBV-transgenic mice, a 
construct of HBV-specific Tc epitope and PADRE could 
break the Tc tolerance [156]. Potent HPV-16 E7-specific 
CD8+ T cell immune responses were generated when 
C57BL/6 mice were injected with HPV-16 E749-57 (9 aa-long 
peptide) in combination with PADRE and 
polyriboinosinic:polyribocytidylic acid [poly (I:C)] [157]. 
Ghaffari-Nazari et al. (2015) demonstrated that the addition 
of the PADRE peptide and CpG adjuvant to synthetic, multi-
epitope, long Her2/neu CTL peptide, P5+435 (44 aa-long 
peptide, inclusive of the RR linker) enhanced Tc immune 
response and anti-tumor effects [145]. In dengue vaccine 
development, a multi-epitope vaccine was designed 
containing a T cell epitope (E345-359), a B cell epitope (E383-
397), both originating from the envelope domain III (EDIII) 
of DENV-2 and PADRE. Mice immunized with this multi-
epitope vaccine generated specific antibodies against EDIII, 
and were able to induce in vitro lymphoproliferation and 
Th1-dominated cytokine release [158]. 
Instead of manually selecting dominant Tc and Th 
epitopes to design a peptide vaccine, an alternative is to use 
either very long synthetic peptides (approximately 100 
amino acids long) [159], or a mixture containing long 
overlapping synthetic peptides spanning the antigen of 
choice [160]. In both cases, the long synthetic peptide used 
will contain the naturally occurring antigen-specific Tc and 
Th epitopes. Due to its length, these synthetic peptides have 
to be processed by the professional APCs, prior to 
presentation on MHC-I or MHC-II receptors. This approach 
therefore offers the advantage of not biasing the Tc or Th 
epitope selection. In addition, as the APC is required to 
proteolytically digest and present the epitopes on HLA-I and 
HLA-II molecules, the in vivo cellular machinery would 
select the correct HLA-restricted epitopes, eliminating the 
laborious (and perhaps erroneous) pre-selection of epitopes. 
 
Other co-stimulatory molecules 
The first signal alone (TCR recognition of antigen 
epitope presented via MHC) is insufficient for T cell 
activation and maturation, and often leads to anergy. The 
second signal of activation is provided upon interaction of 
co-stimulatory molecules expressed on the surfaces of T 
cells and APC.  However, T cell activation and 
differentiation has been shown to occur in the absence of 
APC, if the co-stimulatory molecule was introduced together 
with the first signal. This was demonstrated in a study by den 
Boer et. al. (2001) where mice were injected subcutaneously 
with a Tc epitope derived from the human adenovirus type 5 
E1A in incomplete Freud’s adjuvant (IFA) with or without 
CD40-activating antibodies [161]. They observed that the Tc 
peptide alone was not able to generate E1A-specific Tc 
responses, but mice that received the Tc peptide and CD40 
treatment were completely protected against tumor 
outgrowth [161]. In another study performed in murine 
models, co-injection of a nine-amino acid CD8+ T cell 
epitope peptide originating from HPV-16 E7 protein with 
soluble 4-1BBL, a costimulatory molecule, showed higher 
efficacy in eradicating established TC-1 tumors compared to 
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injection of the peptide alone [162]. In general, co-
stimulatory receptors can be broadly classified into two 
families; the CD28 family (eg. CD28, CTLA-4, ICOS, PD-1 
and BTLA) and the TNFR family (eg. CD27, 4-1BB, CD40, 
TRAIL, CD30 and OX40). Each member appears to be 
important in different phases of the immune response, and 
has been described in detail in a review by Duttagupta et. al. 
[163]. 
 
Adjuvants and carriers for peptide vaccines 
Inclusion of inflammatory cytokines (third signal) 
Adjuvants are agents that can stimulate the immune 
system, and when administered together with vaccines, 
improve the antigenicity of the vaccine. Various molecules 
have been used as adjuvants, including (but not limited to) 
inflammatory cytokines, TLR agonists, emulsions, bacterial 
cell components, carbohydrates, mineral salts or 
combinations of several molecules. In addition to signal 1 
(recognition of MHC presented epitopes by TCR) and signal 
2 (co-stimulation), optimal T-cell activation and maturation 
requires the correct inflammatory cytokine milieu (signal 3) 
[164, 165]. The types of cytokines present in the 
microenvironment of the CD4+ T cells after activation and 
co-stimulation determine the differentiation pathway taken 
by the cell to become Th1, Th2 or Th17 cells [165].  
One of the early experiments to demonstrate the 
requirement of the third signal was performed in an APC-
free environment, using naïve T cells from TCR transgenic 
mice and artificial MHC peptide/protein antigen complexes 
immobilized on inert latex microspheres [166]. It was 
observed that CD8+ T cells required the presence of IL-12 in 
addition to the antigen peptide and IL-2 to have optimal 
differentiation and clonal expansion, while for CD4+ T cells, 
IL-1 was the necessary third signal [166]. More recent 
studies have demonstrated that CD8+ T cells require IL-12 or 
type I IFN to support the expansion of this cell type in vivo. 
In experiments where cells lacked the receptors for IL-12, 
type I IFN, or both, the dependency on the third signal 
changed when different infections were introduced. The 
CD8+ T cell expansion was shown to be dependent on type I 
IFN for choriomeningitis virus (LCMV) infection [164]. In 
vesicular stomatitis virus (VSV) infection, type I IFN was 
able to substitute the function of IL-12 in CD8+ T cell 
expansion [150, 167]. Neither IL-12 nor type I IFN was 
required for cell expansion during vaccinia virus (VV) 
infection [164]. On one hand, it has been reported that high 
amounts of the co-stimulatory signal  IL-2 supported CD8+ T 
cell cytolytic activity and its differentiation into effector Tc, 
[147, 168] and that IL-2 was able to support T cell 
activation, but the question remains if IL-2 is able to 
compensate for IL-12 and type I IFN during vaccinia virus 
infection.  
Another frequently used cytokine adjuvant is the 
granulocyte-monocyte colony stimulating factor (GM-CSF). 
GM-CSF is able to augment both humoral and cellular 
immunity by upregulating the surface expression of MHC-II 
and co-stimulatory molecules, CD40 and CD86 [169], 
enhancing antigen processing and presentation [170]. GM-
CSF has been used successfully as an adjuvant with the 
commercialized HBV vaccine, Engerix-B® [171] and with 
several peptide vaccines in clinical trials [172, 173]. In 
dengue vaccination, the use of GM-CSF has so far been 
restricted to DNA vaccines where it was capable of eliciting 
stronger immune responses [174, 175]. While GM-CSF is 
safe and effective, it’s only disadvantage seems to be its 
short circulating half-life [176], which can be overcome by 
either attaching a polyethylene glycol moiety to GM-CSF 
[177], or by encapsulation in a micro or nanoparticle [178, 
179]. 
 
Toll-like receptor (TLR) agonists  
TLRs are transmembrane proteins that are localized 
either on the cell surface or intracellular components such as 
endosomes. TLRs of the cell surface (TLR1, 2, 4, 5, and 6) 
are primarily involved in detection of extracellular bacterial 
products, while TLRs of the endosomes (TLR 3, 7, 8 and 9) 
target the identification of viral and bacterial nucleic acids 
[180]. TLRs are able to identify pathogen-associated 
microbial patterns (PAMPs) from microorganisms, and 
initiate the signaling cascade of early innate immune 
responses. Agonists of TLR3, 4, 7 and 9 have been shown to 
enhance the efficacy and potency of anti-viral or anti-cancer 
peptide vaccines in mouse models [147, 181-186]. In fact, 
the success of early vaccines is due to its accidental 
contamination with bacterial components that were able to 
elicit TLR activation, providing it the additional “adjuvant 
effect”. Some examples are the lesions from cowpox patients 
that contained vaccinia virus and TLR 9 agonists, and the 
presence of TLR 2, 4 and 9 in the heat-killed Mycobacterium 
tuberculosis, which is a major component of complete 
Freund’s adjuvant [180]. 
TLRs are able to act as adjuvants of the poorly 
immunogenic peptide vaccines, as they can activate dendritic 
cells (DCs) [187]. When DCs are activated, the expression of 
co-stimulatory molecules such as CD80/86 and CD40 get 
upregulated, and are key in subsequent T-cell activation and 
differentiation [188]. In addition, TLR ligands are able to 
recruit MHC molecules from the endosomal recycling 
compartments, and thus enhancing antigen cross-
presentation [189]. TLRs are often used in viral vaccine 
formulation owing to their strong adjuvant properties. 
Imidazoquinoline, a TLR-7/8 agonist, was able to act as an 
adjuvant and broaden responses to the avian influenza virus 
H5N1 HA based antigens in related viral clades, conferring a 
wider protection against this virus [190]. A highly selective 
TLR7 agonist, GS-9620, when administered together with a 
HIV peptide showed increased CD8+ T cell degranulation, 
cytolytic activity and cytokine secretion [190]. Some studies 
performed in humans and mice propose using several TLR 
agonists in combination for a more potent adjuvant effect 
[191, 192]. A combination of three TLRs (TLR 2/6, TLR 3 
and TLR 9) increased protective efficacy of HIV envelope 
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peptide vaccination in mice, compared to when only 2 TLR 
ligands were used. Increased vaccine efficacy was most 
likely due to higher production of IL-15 and its receptor IL-
15Rwhich contributed to the high avidity of T cells to the 
HIV antigen, enhancing viral clearance [191]. In dengue 
vaccine development, a group from Taiwan has evaluated the 
use of CpG oligodeoxynucleotides (a TLR-9 agonist) in a 
subunit vaccine preparation containing dengue-1 envelope 
protein domain III and water-in-oil-in-water emulsion [193]. 
This vaccine preparation was able to induce anti-DENV-1 
neutralizing antibodies and increased IFN-γ secretion from 
splenocytes following in vitro stimulation, unlike another 
preparation formulated using aluminium phosphate [193]. 
The applications of TLR agonists are vast, and has  also been 
shown to be efficacious in the areas of cancer and infection 
immunotherapy [180, 194, 195].  
 
Alum 
 Alum (aluminium hydroxide) is a safe, well-known, 
and US FDA (US Food and Drug Administration)-approved 
adjuvant for human use [196]. Antigens bind to alum by 
adsorption, and the resulting alum-antigen complex has 
enhanced antigen uptake and presentation by APCs [197]. 
Despite the wide use of alum in different vaccine 
formulations, it is a poor activator of DCs, and induces poor 
Th1-associated immune response essential for anti-viral 
vaccines [198].  
Emulsion based carriers 
Complete Freund’s adjuvant (CFA) is one of the 
most commonly used adjuvants in animal research. CFA is 
not approved for human application as it’s too toxic, 
exhibiting high reactogenicity and has reported to cause local 
neurotic ulcers. It is made up of a combination of bacterial 
and emulsion adjuvants, specifically heat killed bacillus 
Calmette-Guérin (BCG) (Mycobacterium bovis strain) and 
mineral oils. The mode of action of CFA is two-pronged: the 
mineral oil encapsulation of antigen provides a depot for 
slow antigen release, favoring phagocytosis. The heat killed 
bacterium activates DCs and the Th1 pathway via its 
adjuvant effect. In animal immunizations, CFA is usually 
only used during the first antigen injection, as it induces a 
strong Th1 dominated inflammatory response at the site of 
injection. For subsequent injections, antigen is injected with 
the less toxic IFA, which lacks the Mycobacterium 
component.  
As synthetic peptide vaccines are poorly 
immunogenic, encapsulation of peptide vaccines are helpful 
as it provides what is known as the “depot effect”, which is a 
prolonged exposure, and slow release from the emulsion to 
ensure a complete immune response. In addition, 
encapsulation protects peptide vaccines against proteolytic 
digestion. However, in some cases, the depot effect has 
resulted in prolonged local chronic infection [10, 140, 199]. 
Additionally, in the absence of the second signal, the depot 
effect can risk promoting CD8+ T cell tolerance, which has 
been observed in vaccination carried out with minimal T cell 
peptides [10, 140, 200, 201].  
Encapsulated carriers are customizable, and are 
either delivered as water-in-oil emulsions, or multi-loaded 
with other adjuvants such as inflammatory cytokines or TLR 
agonists. Two of the newer emulsion based carriers that have 
been used in human vaccinations include MF59 and 
Montanide. MF59 is a microfluidized water-in-oil emulsion 
made up of squalene, polysorbate 80  and sorbitan trioleate 
[202]. It is the first adjuvant to be used in FLUAD®, a 
seasonal influenza vaccine [203, 204]. Montanide™ is 
another family of water-in-oil emulsion adjuvants, of which 
two formulations, Montanide ISA51 (IFA) and Montanide 
ISA720 are specific for human use. Its applications are vast 
and has been used in about 300 clinical trials involving 
vaccines of malaria, AIDS, cancer and autoimmune diseases. 
Commercially, Montanide ISA51 has been used in the 
formulation of CimaVax-EGF, a vaccine against non-small-
cell lung carcinoma [205]. Other squalene-based emulsions 
such as AF03, AS03 and AS04 have also been approved for 
human applications, but are disease and country specific.  
 
Liposomes 
Liposomes are self-assembling vesicular structures 
composed of phospholipid bilayer shell with an aqueous 
core, and have been used extensively as drug delivery 
vehicles [206]. They can be generated as either multilameller 
vesicles which consist of several concentric phospholipid 
shells separated by layers of water, or unilameller vesicles 
made of a single phospholipid bilayer [207, 208]. Liposomes 
are biocompatible and completely biodegradable, making 
them advantageous over other vaccine carriers because of 
their lack of toxicity. Liposome are chemically and 
structurally flexible, and can encapsulate or conjugate to 
either a hydrophilic antigen, or a lipophilic component which 
can intercalate between the lipid molecules, promoting a 
better uptake by APCs due to improved antigen accessibility 
[206]. In addition, surfaces of liposomes can be designed to 
target immune cells and co-deliver immune-stimulatory 
agents, to enhance the immune response [124, 209]. For 
example, liposomes have been used in the delivery of 
diphtheria toxoid in combination with poly (I:C) [209]. It has 
also been approved in vaccine formulations for human use, 
such as Inflexal® (influenza vaccine) and Epaxal V® 
(hepatitis A vaccine) [210, 211]. In the field of dengue 
vaccine research, a novel vaccine candidate was formulated 
using truncated recombinant envelope protein from all 4 
serotypes (DEN-80E) and ionisable cationic lipid 
nanoparticles [212]. Immunization of mice, rodents and non-
human primates with this vaccine formulation was able to 
elicit high titers of DENV neutralizing antibodies, and 
induced DEN-80E specific CD4+ and CD8+ T cell responses 
[212].  
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Virus-like particles (VLPs) 
VLPs are self-assembling nanoparticle structures 
that resemble viruses, composed of viral structural proteins 
(such as capsid and envelope proteins). However, they are 
non-infectious and are unable to replicate as they do not 
contain any viral genetic material. Hence, VLPs are a safer 
alternative to LAVs, having the same external viral protein 
assembly that is capable of inducing strong humoral and 
cell-mediated immunity, without the adverse effects 
associated with LAVs [208, 213, 214]. The use of VLPs as a 
vaccination strategy in dengue has also been explored. 
Recombinant VLPs containing prM and E proteins of each 
dengue serotype were generated in mammalian cells, and 
evaluated for their humoral and cell-mediated immune 
responses in mice [215]. Both monovalent and tetravalent 
VLPs demonstrated specific antibody production and 
neutralizing antibody activity. Splenocytes harvested from 
mice vaccinated with either dengue VLPs or virions were 
then stimulated in vitro with VLPs, and both groups showed 
comparable IFN-γ release, indicating that the VLPs were 
capable of stimulating cell-mediated immunity [215]. In 
another similar study, the secretion of TNF-α and IL-10 were 
reported in mice immunized with tetravalent VLPs 
containing the prM and E proteins [216]. Although the VLP 
approach for dengue vaccination has been shown to be 
efficacious in mice, its effectiveness in humans are yet to be 
tested. These experiments would be important to do, as the 
current knowledge of epitopes point to the fact that dengue 
virus structural proteins (and NS1) mainly elicit the humoral 
response, while the cell mediated-immunity is primarily 
generated against T cell epitopes from the non-structural 




 Several other nanoparticle strategies for the delivery 
of peptide vaccines exist, and are summarized in Table 3. 
Among these nanoparticles, some have been investigated in 
relation to dengue vaccines such as polymeric nanoparticles 
(PLGA and chitosan) and inorganic nanoparticles (carbon 
nanotubes) (Table 3) 
 
 
Table 3. Examples of other nanoparticles used for peptide vaccine delivery 
Nanoparticle Use in dengue 
vaccine 
Example of use 
Immunostimulatory complexes (ISCOMs) No HBV, HSV type I, influenza [208] 
Self-assembling peptide nanoparticles No Cancer [217], avian influenza [218] and HIV [219] 
Polymeric nanoparticles (PLGA) Yes [220] H1N1 [221] 
Polymeric nanoparticles (Chitosan) Yes [222-224] HPV [155] 
Inorganic nanoparticles Yes [225] Influenza A [226], Hepatitis B core proteins [227] 
Ligand Epitope Antigen Presentation System 
(L.E.A.P.S) 
No Influenza, HSV [228] 
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Creative strategies in designing multi-epitope peptide 
vaccines 
Designing a multi-epitope peptide vaccine allows 
for customization of the molecule, in order to stimulate the 
appropriate immune response desired. Using the multi-
epitope strategy, it is possible to “hand-pick” epitopes of 
interest, thereby combining epitopes of interest from 
different protein subunits in one long synthetic peptide. This 
was elegantly demonstrated in a vaccine candidate of 
hepatitis C virus, where the peptide vaccine contained three 
immunodominant CD8+ T cell epitopes from different 
protein subunits, a CD4+ epitope and a B cell epitope [230]. 
When tested in Balb/c mice, this vaccine candidate was able 
to elicit specific HCV IgG1 and IgG2a antibodies, increased 
IFN-γ levels, and a stable and long lasting immune response 
when tested 9 weeks after the last immunization [230]. A 
similar approach was employed in designing an anti-foot and 
mouth disease virus (FMDV) vaccine candidate, consisting 
of tandem repeats of five B cell epitopes from different 
FMDV variants and one T cell epitope [231]. 
Another study combined the approaches of multi-
epitope peptides and subunit vaccine. The multi-epitope 
assembly peptide (MEAP) against herpes simplex virus type 
2 (HSV-2) was constructed by inserting 12 different epitopes 
(six B cell epitopes, four CD4+ T cell epitopes and two CD8+ 
T cell epitopes) into the extracellular fragments of HSV-2 
glycoprotein D [232]. This MEAP construct could be a 
potential vaccine candidate against HSV-2, as it was able to 
completely protect immunized mice against HSV-2 infection 
by eliciting high titers of neutralizing antibodies and cell-
mediated immune responses [232]. 
The peptide vaccine approaches described so far 
have used different epitopes from a single protein.  Creative 
designing of vaccines using multiple peptides derived from 
multiple proteins have been gaining attention of late. In 
cancer, as tumor associated antigen (TAA) expression is 
limited to a proportion of tumors, the use of multi-protein 
peptide vaccine is more advantageous compared to 
traditional single-protein peptide vaccine. Multiple peptides 
originating from different proteins have the possibility of 
targeting higher amounts of Tc, and have shown to be 
effective in studies involving myeloma [233], esophageal 
cancer [234] and non-small cell lung cancer [235]. A multi-
protein peptide vaccine for renal cancer, IMA901, is 
currently undergoing phase III trial [236], and has shown to 
be clinically beneficial. This approach has a potential to be 
explored in the area of dengue, given that Tc epitopes have 
been identified in multiple proteins of a particular dengue 
virus serotype, and that epitopes of all four virus serotypes 
must be included in the final vaccine formulation to confer 
complete protection. 
HLA restriction of epitopes is one of the major 
stumbling blocks in selecting the appropriate epitopes to 
design a successful peptide vaccine. Two different strategies 
could be used to overcome this issue. First, a mixture 
epitopes specific to different HLA molecules could be co-
delivered during vaccination. This approach has been used 
successfully in a phase II trial for melanoma [237]. In this 
study, either 4 or 12 defined melanoma peptides from 
different proteins, melanocytic differentiation proteins 
(tyrosinase and gp100), cancer testis antigens (MAGE-A1, -
A3, -A10 and NY-ESO-1) and five other novel peptides, that 
were restricted to HLA-A1, HLA-A2 and HLA-A3 were co-
delivered with tetanus toxoid peptide, GM-CSF and 
Montanide ISA51 [237]. The authors observed that the more 
complex 12-peptide mixture induced a broader and more 
robust immune response. In addition, despite competition 
due to additional peptides specific to MHC molecules that 
did not match MHC of the patients, immunogenicity of 
individual peptides were maintained [237]. The second 
approach entails the use of T cell epitopes that are 
promiscuous in their binding to HLA. The HLA-DR 
restricted CD4+ T cell epitope of cancer-testis antigen 
HCA587 was shown to behave as a promiscuous epitope, as 
it was able to stimulate T cells in the context of multiple 
HLA-II alleles [238]. In dengue research, the group of 
Ernesto Marques identified DENV-3 T cell epitopes that 
were highly conserved among all four dengue serotypes, and 
demonstrated that these epitopes were also promiscuous in 
their HLA binding, some able to bind to as many as 14 HLA 
molecules [93], making these epitopes promising candidates 
to be used in dengue vaccination. 
Future outlooks in designing peptide vaccines against 
dengue 
In the last few years, there has been concentrated 
research efforts in identifying T- and B- cell epitopes against 
dengue virus. This was reflected in the number of dengue-
specific epitopes deposited in the immune epitope database 
(IEDB). In May 2017, there were 825 HLA-I restricted 
epitopes and 884 HLA-II restricted epitopes, which was a 
significant increase from what was previously reported [38]. 
The DENV proteome is made up of 10 proteins, three 
structural and seven non-structural. The results of multiple 
studies point out that the humoral response is mostly directed 
against the structural proteins (pre-membrane and envelope) 
and NS1 [239, 240], CD8+ T-cell epitopes are concentrated 
in the non-structural region [76] (mainly NS3 and NS5) [19, 
26, 69, 78] and CD4+ T cell epitopes recognize the capsid, 
envelope and NS3 regions [19, 26, 77, 83, 84]. An exception 
CEL-1000 No Malaria [229] 
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is DENV3, where the CD8+ T cell epitopes were found in 
both structural and non-structural proteins [241].  
Dengvaxia®, the only licensed vaccine to date is 
not effective against DENV-1 and -2. As prM and E proteins 
were the only dengue proteins in Dengvaxia® which was 
built on a YFV backbone, it was not surprising that it only 
elicited anti-prM and anti-E antibody responses in 
vaccinated individuals, while no cell-mediated immunity 
was reported, likely due to the absence of dengue NS 
proteins in the vaccine construct. The other two most 
advanced vaccines in clinical trials, DENVax (Takeda) and 
TV003/TV005 (NIAID) is made up entirely of dengue 
proteins, and were therefore able to elicit both humoral and 
T-cell responses against DENV. As these vaccines are 
LAVs, there are two main disadvantages - the significant 
risks associated with its use, and the high cost factor of 
producing tetravalent LAVs. 
 Finding a good dengue vaccine has been difficult 
as the pathogenesis of the disease is complexed by the four 
co-circulating serotypes, and the worsening of the symptoms 
during secondary heterologous infections. An ideal dengue 
vaccine must mimic the natural immune response against the 
natural virus- that is having both humoral and cell-mediated 
immune responses against all four serotypes, while being 
safe, and ideally affordable. HLA-restriction of CD8+ and 
CD4+ T cell epitopes must also be factored in the vaccine 
design. As shown from multiple studies (Table 2), the HLA-
restriction observed in different populations (with regards to 
the protective and susceptible HLA molecules) were 
heterogeneous. Studies done to investigate peptide binding to 
cell lines expressing single HLA molecules or purified HLA 
proteins showed that as several HLA molecules shared 
peptide binding specificities, only a small number of HLA 
needs to be targeted in order to cover the restriction profile 
of the majority of a population [106, 107]. In relation to 
dengue vaccines, once the major protective HLA molecules 
for a certain population has been identified, these HLA-
restrictions should be taken into account to select the 
appropriate Tc epitopes in the multi-epitope vaccine design. 
One of the hallmarks of a successful vaccine 
candidate is its ability to protect against viral infections. In 
the case of peptide vaccines against dengue, this was 
evaluated by first immunizing the mice with the peptides in 
relevant adjuvants, followed by infection using a mouse-
adapted viral strain of dengue. Two groups  have shown that 
different formulations of multi-epitope peptide vaccines 
were able to protect vaccinated mice against dengue viral 
challenge, likely via a combination of humoral and cell-
mediated pathways [69, 158]. Similar promising outlooks 
were reported in peptide vaccines developed against other 
viruses such as influenza [242, 243], vaccinia and variola 
viruses [244] and foot-and-mouth disease virus [245] that 
were able to confer protection when challenged with virus. 
An effective anti-dengue vaccine should be capable 
of eliciting both neutralizing antibodies and activating CD8+ 
cytotoxic T cells to kill virus-infected cells, eventually 
leading to viral clearance from the host. However, it is 
insufficient for a peptide vaccine candidate to elicit high 
levels of peptide-specific IgG antibodies without sufficient  
neutralizing activity [90], as this could be potentially cause 
ADE [246, 247], subsequently leading to severe dengue. The 
live attenuated tetravalent vaccine Dengvaxia® was able to 
elicit high levels of neutralizing antibodies [range: 47% 
(DENV2) to 83% (DENV4)] against all four dengue virus 
serotypes, but still reported poor efficacy against DENV1 
(<58%) and DENV2 (<47%) [31]. This suggests that 
complete immune protection cannot be conferred solely by 
neutralizing antibodies, and should be complemented by the 
cellular immunity. Initial clinical trial data of the three other 
dengue vaccines, two from NIAID [42, 43], one from 
Takeda [46], showed that they were able to stimulate both 
neutralizing antibodies and cytotoxic T cell response against 
dengue virus. However, protective efficacies of both 
vaccines will be known based on the phase III clinical trial 
outcomes. 
The multi-epitope peptide vaccine based strategy 
appears to be an attractive route to pursue as it is safe, 
reproducible and cost-effective. The vaccine will be able to 
elicit both humoral and cellular immunity to mimic the 
natural immune response against dengue as it is comprised 
of B- and T- cell epitope sequences that are highly conserved 
in all four serotypes. Immunogenicity of the peptide vaccine 
may be improved by the addition of adjuvants, and its 
delivery to lymphocyte cells targeted using nanoparticles.  
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